DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/56n27x/protein_kinase) has announced the addition of the "Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2015" report to their offering.
Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition.
There are today 341 companies plus partners developing 590 PKI drugs in 2360 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 443 drugs. Protein Kinase Inhibitors In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them.
Identified drugs are linked to 266 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 258 out of the 263 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 46 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 35
- Registered - 1
- Pre-registration - 7
- Phase III - 61
- Phase II - 204
- Phase I - 264
- Preclinical - 377
- No Data - 11
- Suspended - 4
-
Ceased - 443
For more information visit http://www.researchandmarkets.com/research/56n27x/protein_kinase
